RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:55596

HNRNPDL-related limb-girdle muscular dystrophy D3

high confidenceDisorder

Also known as: Autosomal dominant limb-girdle muscular dystrophy type 1G · HNRNPDL-related LGMD D3 · LGMD type 1G · LGMD1G · Limb-girdle muscular dystrophy type 1G

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

62

45.2th percentile

Trials

0

Interventional, condition-specific

Researchers

355

Distinct authors in sample

Gene link

HNRNPDL

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, mild subtype of limb-girdle muscular characterized by a typically adult onset of mild, , proximal weakness of pelvic and shoulder girdle muscles and , permanent finger and toes flexion limitation without flexion contractures. Normal to highly elevated creatine kinase serum levels are observed.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

HNRNPDL autosomal dominant limb-girdle muscular dystrophy · autosomal dominant limb-girdle muscular dystrophy caused by mutation in HNRNPDL · muscular dystrophy, limb-girdle, autosomal dominant 3

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — HNRNPDL

  2. LiteraturePresent

    62 matched papers (32 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 24 for broader category limb-girdle muscular dystrophy

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (HNRNPDL).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

62

62 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

62 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

32 in the last 10 years · high confidence · 45.2th percentile (publications denominator)

Phrase hits: 62 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

355

Distinct author names in 62 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Ventura S5 papers · 2022

    Institut de Biotecnologia i Biomedicina, Departament de Bioquimica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. salvador.ventura@uab.es.

    Papers in Europe PMC
  2. 02
    Batlle C3 papers · 2020

    Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain.

    Papers in Europe PMC
  3. 03
    Li X3 papers · 2023

    Key Laboratory of Animal Breeding and Healthy Livestock Farming, College of Animal Science and Veterinary Medicine, Tianjin Agricultural University, Tianjin 300392, China.

    Papers in Europe PMC
  4. 04
    Schneider RJ3 papers · 2021

    Department of Microbiology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

    Papers in Europe PMC
  5. 05
    Vainzof M3 papers · 2016

    Human Genome and Research Center (HUG-CELL), Instituto de Biociências, Universidade de São Paulo (USP), São Paulo, SP, Brazil.

    Papers in Europe PMC
  6. 06
    Zatz M3 papers · 2016

    Human Genome and Research Center (HUG-CELL), Instituto de Biociências, Universidade de São Paulo (USP), São Paulo, SP, Brazil.

    Papers in Europe PMC
  7. 07
    Abbadi D2 papers · 2021

    Department of Microbiology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

    Papers in Europe PMC
  8. 08
    An L2 papers · 2016

    Department of Biology, McGill University, Montreal, QC, Canada.

    Papers in Europe PMC
  9. 09
    Andrews JJ2 papers · 2021

    Department of Microbiology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

    Papers in Europe PMC
  10. 10
    Bartoli M2 papers · 2013
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 24 trials are registered for limb-girdle muscular dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

24 interventional trials matched limb-girdle muscular dystrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: limb-girdle muscular dystrophy

24

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"HNRNPDL-related limb-girdle muscular dystrophy D3" OR "Autosomal dominant limb-girdle muscular dystrophy type 1G" OR "HNRNPDL-related LGMD D3" OR "LGMD type 1G" OR "LGMD1G" OR "Limb-girdle muscular dystrophy type 1G" OR "HNRNPDL autosomal dominant limb-girdle muscular dystrophy" OR "autosomal dominant limb-girdle muscular dystrophy caused by mutation in HNRNPDL" OR "muscular dystrophy, limb-girdle, autosomal dominant 3"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Limb-Girdle Muscular Dystrophy, Type 1G

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"HNRNPDL-related limb-girdle muscular dystrophy D3" OR "Autosomal dominant limb-girdle muscular dystrophy type 1G" OR "HNRNPDL-related LGMD D3" OR "LGMD type 1G" OR "LGMD1G" OR "Limb-girdle muscular dystrophy type 1G" OR "HNRNPDL autosomal dominant limb-girdle muscular dystrophy" OR "autosomal dominant limb-girdle muscular dystrophy caused by mutation in HNRNPDL" OR "muscular dystrophy, limb-girdle, autosomal dominant 3" OR "Limb-Girdle Muscular Dystrophy, Type 1G" OR "HNRNPDL" OR "muscular dystrophy, limb-girdle, autosomal dominant"

Recall-expansion terms: HNRNPDL, muscular dystrophy, limb-girdle, autosomal dominant

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"limb-girdle muscular dystrophy"

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:57:42.046Z